Yvonne van der Meer

Yvonne van der Meer

Auto-generated profile, based on publicly available information

Yvonne van der Meer

Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Antiviral Research
Verified
Journal Article
Open access
CSClarisse Salgado-Benvindo
Clarisse Salgado-Benvindo
ATAli Tas
Ali Tas
JZJessika C. Zevenhoven-Dobbe
Jessika C. Zevenhoven-Dobbe
YMYvonne van der Meer
Yvonne van der Meer
ISIgor Sidorov
Igor Sidorov
MHMartijn Van Hemert
Martijn Van Hemert
A range of cell culture infection models have been used to study SARS-CoV-2 and perform antiviral drug research. Commonly used African green monkey Vero, human lung-derived Calu-3 and ACE2+TMPRSS2-expressing A549 cells, each have their limitations. Here, we describe human ACE2-expressing H1299 lung cells as a more efficient and robust model for SARS-CoV-2 research. These cells are as easy to handle as Vero cells, support SARS-CoV-2 replication to high titers, display a functional innate immune response and are suitable for plaque assays, microscopy, the production of (genetically stable) virus stocks and antiviral assays. H1299/ACE2-based (CPE reduction) assays can be performed without adding a P-gP drug efflux pump inhibitor, which is often required in Vero-based assays. Moreover, H1299/ACE2 cells allowed us to perform CPE reduction assays with omicron variants that did not work in Vero-based assays. In summary, H1299/ACE2 cells are a versatile infection model to study SARS-CoV-2 replication in the context of antiviral drug development and virus-host interaction studies.